https://www.clinicaloncology.com/Hematologic-Malignancies/Article/07-24/Sussing-Out-a-2nd-Cancer-Signal-for-CAR-T-Therapy/74117
https://www.clinicaloncology.com/Current-Practice/Article/07-24/New-WHO-Guidance-Aims-to-Reduce-Catheter-Related-Bloodstream-Infections/74118
https://www.clinicaloncology.com/Community-Oncology/Article/07-24/Study-in-Oncologic-Surgery-Patients-Confirms-Opioid-Sparing-Effects-of-Clinical-Hypnosis/74144
https://www.clinicaloncology.com/Current-Practice/Article/07-24/Surgeon-Well-Being-ACS-Survey/74264
https://www.clinicaloncology.com/Solid-Tumors/Article/07-24/For-Patients-With-EGFR-Mutated-Lung-Cancer-Osimertinib-Trial-Might-Change-Guidelines/74268
https://www.clinicaloncology.com/Community-Oncology/Article/07-24/Community-Oncology-Alliance-Executive-Director-Weighs-In-on-Issues-Affecting-Community-Oncology-Care/74267
https://www.clinicaloncology.com/Community-Oncology/Article/07-24/Adding-IT-Clonidine-Beneficial-for-Cancer-Pain-Patients/74298
https://www.clinicaloncology.com/Current-Practice/Article/07-24/Bill-for-Home-Infusion-Benefit-Still-Awaiting-Congressional-Score/74305
https://www.clinicaloncology.com/Solid-Tumors/Article/07-24/Guideline-Change-for-Resectable-Esophageal-Cancer/74299
https://www.clinicaloncology.com/Solid-Tumors/Article/07-24/Aging-Surgeons-Challenges-Competency/74306
https://www.clinicaloncology.com/Community-Oncology/Article/07-24/Hardy-Diagnostics-Releases-Enrichment-Broth-for-C-auris-Detection/74362
https://www.clinicaloncology.com/COVID-19/Article/07-24/Cannabis-Severe-COVID-19-Risk/74307
https://www.clinicaloncology.com/Solid-Tumors/Article/07-24/stigmatizing-language-liver-transplant-websites-alcohol-use-disorder/74308
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/07-24/Large-Data-Set-Sheds-Light-on-Rate-of-CAR-T-Side-Effects/74309
https://www.clinicaloncology.com/Solid-Tumors/Article/07-24/endoscopic-submucosal-dissection-with-traction-esophageal-cancer/74311
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/08-24/FDA-Approves-Darzalex-Faspro-With-Bortezomib-Lenalidomide-and-Dexamethasone-for-Multiple-Myeloma/74441
https://www.clinicaloncology.com/Solid-Tumors/Article/08-24/cfDNA-blood-screening-CRC-approval-Shield-Guardant/74452
https://www.clinicaloncology.com/Solid-Tumors/Article/08-24/FDA-Expands-Endometrial-Cancer-Indication-for-Jemperli-With-Chemotherapy/74454
https://www.clinicaloncology.com/Solid-Tumors/Article/08-24/Randomized-Trial-Validates-Virtual-Early-Palliative-Care-for-Lung-Cancer/74363
https://www.clinicaloncology.com/Solid-Tumors/Article/08-24/FDA-Grants-Accelerated-Approval-to-Tecelra-for-Unresectable-or-Metastatic-Synovial-Sarcoma/74465
https://www.clinicaloncology.com/Community-Oncology/Article/08-24/New-Guidelines-Help-Rural-Pain-Centers-Better-Treat-Patients/74364
https://www.clinicaloncology.com/Solid-Tumors/Article/08-24/Trastuzumab-Deruxtecan-Beats-Standard-Even-in-Very-Low-HER2-Metastatic-Breast-Cancer/74365
https://www.clinicaloncology.com/Solid-Tumors/Article/08-24/Voranigo-Approved-for-Astrocytoma-or-Oligodendroglioma-With-a-Susceptible-IDH1-or-IDH2-Mutation/74516
https://www.clinicaloncology.com/Solid-Tumors/Article/08-24/Influenza-Vaccines-Solid-Organ-Transplants/74366
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/08-24/Lymphir-Approved-for-Adults-With-Relapsed-or-Refractory-Cutaneous-T-Cell-Lymphoma/74534
https://www.clinicaloncology.com/Solid-Tumors/Article/08-24/Robotic-Hepatectomy-Difficulty-Scoring-Systems/74367
https://www.clinicaloncology.com/Community-Oncology/Article/08-24/App-Help-Cancer-Patients-Manage-Pain/74368
https://www.clinicaloncology.com/Community-Oncology/Article/08-24/FDA-Approves-Niktimvo-for-Chronic-Graft-Versus-Host-Disease/74599
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/08-24/Resolving-CAR-T-Complications-in-the-ICU/74433
https://www.clinicaloncology.com/Solid-Tumors/Article/08-24/FDA-Approves-Neoadjuvant-Adjuvant-Imfinzi-for-Resectable-NSCLC/74622
https://www.clinicaloncology.com/Solid-Tumors/Article/08-24/FDA-Approves-Lazcluze-With-Rybrevant-for-Non-Small-Cell-Lung-Cancer/74641
https://www.clinicaloncology.com/Current-Practice/Article/08-24/Congress-Demands-Answers-From-PBMs/74643
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/08-24/Researchers-Identify-Genes-Linked-to-Relapse-in-Standard-Risk-B-Cell-Acute-Lymphoblastic-Leukemia/74573
https://www.clinicaloncology.com/Community-Oncology/Article/08-24/Cognitive-Behavioral-Therapy-Benefits-Cancer-Survivors/74667
https://www.clinicaloncology.com/Solid-Tumors/Article/08-24/Anal-Cancer-Risk-Differs-by-Region-for-People-With-HIV/74435
https://www.clinicaloncology.com/Current-Practice/Article/09-24/Smishing-Cyberattacks-Hook-Personal-Data/74434
https://www.clinicaloncology.com/Community-Oncology/Article/09-24/Strategies-for-Managing-Nutritional-Complications-Of-Novel-Cancer-Therapies/74642
https://www.clinicaloncology.com/Solid-Tumors/Article/09-24/colon-cancer-screening-early-adenomas-increased-cancer-death/74436
https://www.clinicaloncology.com/Current-Practice/Article/09-24/Societies-Call-for-Broader-Treatment-Options-For-End-of-Life-and-Palliative-Pain-Care/74644
https://www.clinicaloncology.com/Community-Oncology/Article/09-24/Aspergillus-Infections-Detection-Method/74647
https://www.clinicaloncology.com/Solid-Tumors/Article/09-24/FDA-Approves-Tecentriq-Hybreza-for-Subcutaneous-Injection-for-All-Adult-Indications-of-IV-Tecentriq/74858
https://www.clinicaloncology.com/Current-Practice/Article/09-24/FDA-Issues-Draft-Guidance-on-Conducting-Multiregional-Clinical-Trials-in-Oncology/74871
https://www.clinicaloncology.com/Solid-Tumors/Article/09-24/Kisqali-With-an-AI-and-Kisqali-Femara-Co-Pack-Approved-for-Early-High-Risk-Breast-Cancer/74872
https://www.clinicaloncology.com/Current-Practice/Article/09-24/Few-Studies-and-Variable-Opioid-Misuse-Rates-in-Cancer-Patients-Highlight-Need-for-Better-Research/74650
https://www.clinicaloncology.com/Solid-Tumors/Article/09-24/FDA-Approves-Keytruda-With-Chemo-for-Unresectable-Advanced-or-Metastatic-Malignant-Pleural-Mesothelioma/74887
https://www.clinicaloncology.com/Solid-Tumors/Article/09-24/fecal-immunochemical-testing-FIT-reducing-cancer-deaths-CRC/74651
https://www.clinicaloncology.com/Solid-Tumors/Article/09-24/-FDA-Approves-Rybrevant-for-NSCLC-With-EGFR-Exon-19-Deletions-or-L858R-Mutations/74918
https://www.clinicaloncology.com/Solid-Tumors/Article/09-24/Robotic-Assisted-Surgery-Colon-Cancer/74649
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/09-24/-FDA-Approves-Sarclisa-With-Bortezomib-Lenalidomide-and-Dexamethasone-for-Newly-Diagnosed-Multiple-Myeloma/74927
https://www.clinicaloncology.com/Community-Oncology/Article/09-24/Drug-to-Treat-Cachexia-in-Cancer-Patients-Shows-Promise-in-Trial/74941
https://www.clinicaloncology.com/Solid-Tumors/Article/09-24/Tagrisso-Approved-for-Some-With-Locally-Advanced-Unresectable-Stage-III-NSCLC-Following-Chemoradiation/74948
https://www.clinicaloncology.com/Current-Practice/Article/09-24/More-Needs-to-Be-Done-to-Address-Financial-Toxicity-in-AYA-Cancer-Patients/74943
https://www.clinicaloncology.com/Solid-Tumors/Article/09-24/Esophageal-Fluorescence-Guided-Surgery-Advancements/74866
https://www.clinicaloncology.com/Solid-Tumors/Article/09-24/FDA-Fully-Approves-Retevmo-for-RET-Fusion-Positive-Medullary-Thyroid-Cancer/74993
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/10-24/CAR-Ts-and-BiTEs-The-Cost-and-Efficacy-Equation/74868
https://www.clinicaloncology.com/Solid-Tumors/Article/10-24/FDA-Approves-Neoadjuvant-Adjuvant-Opdivo-for-Resectable-NSCLC/75064
https://www.clinicaloncology.com/Community-Oncology/Article/10-24/Strong-Weapons-Needed-to-Combat-Antimicrobial-Resistance/74870
https://www.clinicaloncology.com/Solid-Tumors/Article/10-24/Breast-Cancer-Axillary-Ultrasound-SOUND-Trial/74864
https://www.clinicaloncology.com/Solid-Tumors/Article/10-24/Overall-Survival-Benefit-Supports-New-Standard-in-High-Risk-Locally-Advanced-Cervical-Cancer/75132
https://www.clinicaloncology.com/Solid-Tumors/Article/10-24/Itovebi-With-Palbociclib-and-Fulvestrant-Approved-for-Some-Advanced-Breast-Cancer-Patients/75140
https://www.clinicaloncology.com/Solid-Tumors/Article/10-24/Breast-Cancer-Chronic-Pain-Prediction/74869
https://www.clinicaloncology.com/Solid-Tumors/Article/10-24/Adding-Checkpoint-Inhibitor-to-Therapy-Improves-Overall-Survival-in-Bladder-Cancer/75159
https://www.clinicaloncology.com/Community-Oncology/Article/10-24/New-Guidance-for-AMR-Gram-Negative-Infections/74865
https://www.clinicaloncology.com/Solid-Tumors/Article/10-24/Skin-Fungus-Colonization-Accelerates-Breast-Cancer-Tumor-Growth/75160
https://www.clinicaloncology.com/Solid-Tumors/Article/10-24/Vyloy-With-Chemotherapy-Approved-for-Gastric-or-Gastroesophageal-Junction-Adenocarcinoma/75219
https://www.clinicaloncology.com/Solid-Tumors/Article/10-24/new-onset-diabetes-pancreatic-cancer-signs/75218
https://www.clinicaloncology.com/Solid-Tumors/Article/10-24/Quantitative-Counseling-Breast-Cancer/75229
https://www.clinicaloncology.com/Solid-Tumors/Article/10-24/cologuard-plus-approval-next-gen-mt-sDNA-test-CRC-screening/75241
https://www.clinicaloncology.com/Solid-Tumors/Article/10-24/Early-Survival-Benefit-Validates-Addition-of-Radium-244-to-Metastatic-Prostate-Cancer/75297
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/10-24/-FDA-Grants-Accelerated-Approval-to-Scemblix-for-Newly-Diagnosed-Chronic-Myeloid-Leukemia/75318
https://www.clinicaloncology.com/Solid-Tumors/Article/10-24/Addition-of-Retifanlimab-to-Chemotherapy-Called-New-Standard-for-Anal-Cancer/75323
https://www.clinicaloncology.com/Current-Practice/Article/11-24/FDA-Approves-Orlynvah-the-First-Oral-Penem/75303
https://www.clinicaloncology.com/Current-Practice/Article/11-24/CDC-Recommends-Second-Dose-of-2024-2025-COVID-19-Vaccine-for-Older-or-Immunocompromised-People/75324
https://www.clinicaloncology.com/Current-Practice/Article/11-24/UN-Declares-Plan-Combatting-AMR/75326
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/11-24/FDA-Approves-Aucatzyl-for-Adults-With-Relapsed-or-Refractory-B-Cell-Precursor-ALL/75422
https://www.clinicaloncology.com/Solid-Tumors/Article/11-24/Expert-Taps-Best-Papers-In-Breast-Cancer-From-Last-Year/75421
https://www.clinicaloncology.com/Solid-Tumors/Article/11-24/Same-Day-Discharge-Colectomy-Advantages/75427
https://www.clinicaloncology.com/Community-Oncology/Article/11-24/Oncology-Pipeline-Exciting-Breakthroughs-Cited-at-AMCP-Nexus-2024/75458
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/11-24/FDA-Approves-Revuforj-for-Relapsed-or-Refractory-Acute-Leukemia-With-a-KMT2A-Translocation/75474
https://www.clinicaloncology.com/Solid-Tumors/Article/11-24/Breathing-New-Life-Into-the-NSCLC-Pipeline/75476
https://www.clinicaloncology.com/Community-Oncology/Article/11-24/Drug-Labeling-for-Fludarabine-Phosphate-Updated-Under-FDAs-Project-Renewal/75507
https://www.clinicaloncology.com/Community-Oncology/Article/11-24/Whats-New-in-Antifungal-Therapy/75483
https://www.clinicaloncology.com/Solid-Tumors/Article/11-24/First-Line-Pembrolizumab-Improves-Survival-in-Triple-Negative-Breast-Cancer/75534
https://www.clinicaloncology.com/Solid-Tumors/Article/11-24/FDA-Grants-Accelerated-Approval-to-Ziihera-for-Some-People-With-Biliary-Tract-Cancer/75545
https://www.clinicaloncology.com/Solid-Tumors/Article/11-24/10-Year-Survival-Rates-Near-80-for-Melanoma-Patients-Responding-to-Checkpoint-Inhibitors/75533
https://www.clinicaloncology.com/Community-Oncology/Article/12-24/Cyberattacks-on-Hospitals-Proliferate-With-Smishing-/75535
https://www.clinicaloncology.com/Solid-Tumors/Article/12-24/Annual-Breast-MRI-Screening-Debate/75536
https://www.clinicaloncology.com/Solid-Tumors/Article/12-24/FDA-Grants-Accelerated-Approval-to-Bizengri-for-NSCLC-and-Pancreatic-Adenocarcinoma/75653
https://www.clinicaloncology.com/Solid-Tumors/Article/12-24/FDA-Approves-Imfinzi-for-Limited-Stage-Small-Cell-Lung-Cancer/75654
https://www.clinicaloncology.com/Solid-Tumors/Article/12-24/Bolus-Omission-Gastrointestinal-Cancer-Survival/75593
https://www.clinicaloncology.com/Current-Practice/Article/12-24/Oral-Oncolytics-Adverse-Events-Monitoring/75641
https://www.clinicaloncology.com/Solid-Tumors/Article/12-24/artificial-intelligence-colonoscopy-CADe-CADx/75642
https://www.clinicaloncology.com/Solid-Tumors/Article/12-24/FDA-Approves-Unloxcyt-for-Metastatic-or-Locally-Advanced-Cutaneous-Squamous-Cell-Carcinoma/75753
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/12-24/Addition-of-Second-Monoclonal-Antibody-Improves-Outcomes-of-Follicular-Lymphoma/75763
https://www.clinicaloncology.com/Solid-Tumors/Article/12-24/FDA-Approves-Ensacove-for-ALK-Positive-Locally-Advanced-or-Metastatic-NSCLC/75769
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/12-24/FDA-Approves-Ryoncil-for-Steroid-Refractory-Acute-Graft-Versus-Host-Disease-in-Pediatric-Patients/75775
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/12-24/T-Cell-Engager-Called-Major-Breakthrough-In-Children-With-B-Cell-ALL/75781
https://www.clinicaloncology.com/Solid-Tumors/Article/12-24/Breast-Cancer-Population-Based-Genetic-Testing-Versus-Guideline-Based-Screening/75782
https://www.clinicaloncology.com/Solid-Tumors/Article/12-24/FDA-Grants-Accelerated-Approval-to-Braftovi-for-Some-Patients-With-Metastatic-Colorectal-Cancer/75797
https://www.clinicaloncology.com/Solid-Tumors/Article/12-24/Fluorescence-Imaging-Oncoplastic-Breast-Surgery/75783
https://www.clinicaloncology.com/Solid-Tumors/Article/12-24/FDA-Approves-Opdivo-Qvantig-for-Subcutaneous-Injection/75808
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/01-25/Hematopoietic-Transplant-Appears-Superfluous-in-Many-Mantle-Cell-Lymphoma-Patients/75821
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/01-25/Is-There-a-Smarter-Way-to-Treat-Fungal-Infections-in-Patients-With-Blood-Cancer/75822
https://www.clinicaloncology.com/FDA-Watch/Article/01-25/FDA-News-Appears-Elsewhere-on-Clinical-Oncology-News-Website/77637
https://www.clinicaloncology.com/Community-Oncology/Article/01-25/Future-Bright-Oncology-Development/75823
https://www.clinicaloncology.com/Solid-Tumors/Article/01-25/Tevimbra-Approved-for-Treatment-of-Gastric-and-Gastroesophageal-Junction-Cancers-in-Combination-With-Chemo/75965
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/01-25/Blinatumomab-Increases-Disease-Free-Survival-for-Children-With-Leukemia/75824
https://www.clinicaloncology.com/Solid-Tumors/Article/01-25/Breakthrough-in-EGFR-Mutated-NSCLC-Rybrevant-Plus-Lazcluze-Extends-Overall-Survival/75981
https://www.clinicaloncology.com/Community-Oncology/Article/01-25/Glucarpidase-Boosts-Recovery-From-Methotrexate-Induced-Acute-Kidney-Injury/75982
https://www.clinicaloncology.com/Solid-Tumors/Article/01-25/FDA-Approves-Lumakras-With-Vectibix-for-KRAS-G12C-Mutated-Colorectal-Cancer/76016
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/01-25/FDA-Approves-Calquence-With-Bendamustine-and-Rituximab-for-Previously-Untreated-Mantle-Cell-Lymphoma/76019
https://www.clinicaloncology.com/Solid-Tumors/Article/01-25/-FDA-Approves-Datroway-for-Unresectable-or-Metastatic-HR-positive-HER2-negative-Breast-Cancer/76031
https://www.clinicaloncology.com/Solid-Tumors/Article/01-25/Environmental-Exposure-a-Risk-Factor-for-Breast-Cancer/76047
https://www.clinicaloncology.com/Community-Oncology/Article/01-25/Public-Health-Experts-Criticize-WHO-Withdrawal/76057
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/01-25/Paving-the-Way-for-First-Line-Oral-Doublet-in-CLL/76062
https://www.clinicaloncology.com/Solid-Tumors/Article/01-25/Rise-in-Breast-Cancer-Among-Young-Women-Requires-New-Models-of-Care/76063
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/02-25/Harnessing-the-Potential-of-CAR-T-Cell-Therapy-for-Multiple-Myeloma/76127
https://www.clinicaloncology.com/Breast-Cancer/Article/02-25/Is-Breast-Cancer-Metastasis-a-Hereditary-Disorder/76197
https://www.clinicaloncology.com/Current-Practice/Article/02-25/FDA-Approves-Emblaveo-to-Treat-Certain-Complicated-Intraabdominal-Infections/76239
https://www.clinicaloncology.com/Solid-Tumors/Article/02-25/AI-Stool-Test-Colorectal-Cancer-CRC/76265
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/02-25/FDA-Approves-Preparative-Regimen-for-allo-HSCT-in-Patients-With-AML-or-MDS/76290
https://www.clinicaloncology.com/Community-Oncology/Article/02-25/Gomekli-Approved-for-Patients-With-Neurofibromatosis-Type-1/76291
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/02-25/FDA-Approves-Adcetris-With-Lenalidomide-and-Rituximab-for-Relapsed-or-Refractory-Large-B-Cell-Lymphoma/76292
https://www.clinicaloncology.com/Solid-Tumors/Article/02-25/FDA-Approves-Romvimza-for-Symptomatic-Tenosynovial-Giant-Cell-Tumor/76293
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/02-25/Daratumumab-Delays-Transition-From-Smoldering-to-Active-Multiple-Myeloma/76294
https://www.clinicaloncology.com/Solid-Tumors/Article/02-25/Managing-Respiratory-Distress-Symptoms-in-People-with-Lung-Cancer/76318
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/02-25/Novel-Therapy-Shows-Impressive-Activity-in-Heavily-Pretreated-CLL/76319
https://www.clinicaloncology.com/Solid-Tumors/Article/02-25/Genetic-Testing-Role-Gastroenterology-Cancer-GI/76340
https://www.clinicaloncology.com/Breast-Cancer/Article/03-25/Cryoablation-Breast-Cancer-Treatment/76403
https://www.clinicaloncology.com/Solid-Tumors/Article/03-25/Signals-From-Lungs-of-Cancer-Patients-May-Cause-Thrombosis/76404
https://www.clinicaloncology.com/Current-Practice/Article/03-25/FDA-Approves-Novel-Nonopioid-Treatment-for-Moderate-to-Severe-Acute-Pain/76405
https://www.clinicaloncology.com/Solid-Tumors/Article/03-25/Tevimbra-Approved-for-Some-Patients-With-Unresectable-or-Metastatic-ESCC/76407
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/03-25/Mesalamine-Launch-Amneal/76415
https://www.clinicaloncology.com/Community-Oncology/Article/03-25/Community-Oncology-Alliance-Releases-Comprehensive-Legislative-Framework-for-Healthcare-Reform/76423
https://www.clinicaloncology.com/Community-Oncology/Article/03-25/FDA-Highlights-Importance-of-DPD-Deficiency-Discussions-With-Patients-Before-Capecitabine-or-5-FU-Treatment/76424
https://www.clinicaloncology.com/Current-Practice/Article/03-25/The-NOPAIN-Act-An-Opportunity-for-Collaboration-Improvement-in-Pain-Outcomes/76416
https://www.clinicaloncology.com/Current-Practice/Article/03-25/FDA-Vaccine-Advisory-Committee-Meeting-Canceled/76441
https://www.clinicaloncology.com/COVID-19/Article/03-25/Pemivibart-Monoclonal-Antibody-COVID/76454
https://www.clinicaloncology.com/Reviews-and-Commentaries/Article/03-25/Chronic-Lymphocytic-Leukemia-Treatment-Management/76417
https://www.clinicaloncology.com/Solid-Tumors/Article/03-25/High-Rates-of-Polypharmacy-Among-Lung-Cancer-Patients-Even-Younger-Adults/76418
https://www.clinicaloncology.com/Current-Practice/Article/03-25/New-Guidance-May-Help-Reduce-Delirium-Risk-in-Older-Patients-Undergoing-Surgery/76419
https://www.clinicaloncology.com/Community-Oncology/Article/03-25/Rezafungin-Efficacy-Candidemia-Treatment/76420
https://www.clinicaloncology.com/Current-Practice/Article/03-25/Automated-Cancer-Patient-Follow-up/76421
https://www.clinicaloncology.com/Solid-Tumors/Article/03-25/Keytruda-Receives-Traditional-Approval-for-Some-Patients-With-HER2-Positive-Gastric-or-GEJ-Adenocarcinoma/76560
https://www.clinicaloncology.com/Current-Practice/Article/03-25/Reports-Assess-Oncology-Workforce-Well-Being-and-Propose-Solutions-to-Burnout/76541
https://www.clinicaloncology.com/COVID-19/Article/03-25/FDA-Extends-Expiration-Dates-for-COVID-19-Tests/76584
https://www.clinicaloncology.com/Solid-Tumors/Article/03-25/Cryotherapy-Treatment-Esophageal-Cancer/76587
https://www.clinicaloncology.com/Solid-Tumors/Article/03-25/AI-Assisted-Colonoscopy-Benign-Lesions-Resection/76591
https://www.clinicaloncology.com/Solid-Tumors/Article/03-25/FDA-Approves-Cabometyx-for-pNET-and-epNET/76610
https://www.clinicaloncology.com/Current-Practice/Article/03-25/FDA-Approves-First-in-Class-Blujepa-to-Treat-uUTIs-in-Females-12-and-Older/76631
https://www.clinicaloncology.com/Current-Practice/Article/03-25/Guidelines-Sought-for-Managing-Risks-of-Long-Term-Opioid-Therapy-Discontinuation/76592
https://www.clinicaloncology.com/Solid-Tumors/Article/03-25/Breast-Cancer-Treatment-Advances/76593
https://www.clinicaloncology.com/Solid-Tumors/Article/03-25/FDA-Approves-Imfinzi-for-Muscle-Invasive-Bladder-Cancer/76675
https://www.clinicaloncology.com/Solid-Tumors/Article/03-25/FDA-Expands-Pluvictos-Metastatic-Castration-Resistant-Prostate-Cancer-Indication/76726
https://www.clinicaloncology.com/Solid-Tumors/Article/04-25/Exercise-Can-Lessen-Fatigue-in-Prostate-Cancer-Patients-Undergoing-ADT/76674
https://www.clinicaloncology.com/Current-Practice/Article/04-25/Malnutrition-Monitoring-Ambulatory-Cancer-Clinics/76671
https://www.clinicaloncology.com/Solid-Tumors/Article/04-25/Survivorship-Planning-for-Melanoma-Patients/76672
https://www.clinicaloncology.com/Current-Practice/Article/04-25/DEA-Warns-of-EHR-Hacking-Fraud/76673
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/04-25/Amneal-Boruzu-Subcutaneous-Formulation-Launch/76791
https://www.clinicaloncology.com/Community-Oncology/Article/04-25/Chronic-Postsurgical-Pain-Gets-a-New-ICD-11-Definition/76796
https://www.clinicaloncology.com/COVID-19/Article/04-25/Long-COVID-Disproportionately-Affects-Women-Study-Says/76786
https://www.clinicaloncology.com/Community-Oncology/Article/04-25/Light-Intensity-Daily-Physical-Activity-Linked-to-Lower-Cancer-Risk/76784
https://www.clinicaloncology.com/Solid-Tumors/Article/04-25/FDA-Approves-Opdivo-With-Yervoy-for-Unresectable-or-Metastatic-MSI-H-or-dMMR-Colorectal-Cancer/76799
https://www.clinicaloncology.com/Community-Oncology/Article/04-25/Guide-on-Cancer-Related-Cognitive-Impairment-Published/76785
https://www.clinicaloncology.com/Current-Practice/Article/04-25/Tariffs-Pharmaceutical-Impacts/76847
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/04-25/A-Good-Year-for-CAR-T-Therapies/76787
https://www.clinicaloncology.com/Solid-Tumors/Article/04-25/-FDA-Approves-Opdivo-With-Yervoy-for-Unresectable-or-Metastatic-Hepatocellular-Carcinoma/76831
https://www.clinicaloncology.com/COVID-19/Article/04-25/Ensitrelvir-Reduced-the-Risk-for-COVID-19-by-67/76849
https://www.clinicaloncology.com/Solid-Tumors/Article/04-25/EHR-Based-Risk-Model-Shows-Potential-To-Improve-Gastric-Cancer-Screening/76788
https://www.clinicaloncology.com/Current-Practice/Article/04-25/STAQ-Pharma-Oncology-Collaboration/76848
https://www.clinicaloncology.com/Solid-Tumors/Article/04-25/Adjuvant-Nivolumab-Bladder-Cancer-Effective/76850
https://www.clinicaloncology.com/Solid-Tumors/Article/04-25/Skin-Cancer-Diagnosis-Technology-Advancement/76790
https://www.clinicaloncology.com/Community-Oncology/Article/04-25/Music-Tempo-a-Factor-in-Pain-Reduction/76792
https://www.clinicaloncology.com/Current-Practice/Article/04-25/Just-Say-No-to-Paying-Cybersecurity-Ransom/76793
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/04-25/-Statins-May-Improve-Survival-in-Patients-With-CLL-or-SLL/76895
https://www.clinicaloncology.com/Community-Oncology/Article/04-25/Polypharmacy-Cancer-Adults-Prevalence/76794
https://www.clinicaloncology.com/Current-Practice/Article/04-25/Trump-Executive-Order-Drug-Prices/76939
https://www.clinicaloncology.com/Solid-Tumors/Article/04-25/FDA-Approves-Penpulimab-for-Non-Keratinizing-Nasopharyngeal-Carcinoma/76938
https://www.clinicaloncology.com/Solid-Tumors/Article/04-25/Self-Hypnosis-May-Aid-Recovery-Pathway-For-Patients-After-Surgery/76795
https://www.clinicaloncology.com/Current-Practice/Article/04-25/Oncology-Pharmacists-a-Valuable-Addition-to-Cancer-Care-Team/76957
https://www.clinicaloncology.com/Community-Oncology/Article/04-25/Topical-Gel-Relieves-Painful-Rash-Caused-by-Anti-EGFR-Therapies/76989
https://www.clinicaloncology.com/Solid-Tumors/Article/05-25/Schistosoma-Cervical-Cancer-Genes/76990
https://www.clinicaloncology.com/Solid-Tumors/Article/05-25/Liposomal-Bupivacaine-Reduces-Opioid-Consumption-After-Liver-Resection/76991
https://www.clinicaloncology.com/Community-Oncology/Article/05-25/International-Guideline-Released-to-Manage-Candida-Infections/76992
https://www.clinicaloncology.com/Current-Practice/Article/05-25/-First-and-Only-Ready-to-Dilute-Multi-Dose-Vial-of-Thiotepa-Approved/77047
https://www.clinicaloncology.com/Solid-Tumors/Article/05-25/FDA-Grants-Accelerated-Approval-to-Avmapki-Fakzynja-Co-pack-for-Some-Ovarian-Cancers/77069
https://www.clinicaloncology.com/Solid-Tumors/Article/05-25/New-Screening-Surveillance-Approaches-For-BE-May-Uncover-More-Cancers/77011
https://www.clinicaloncology.com/Community-Oncology/Article/05-25/Olanzapine-Found-Effective-for-Managing-TKI-Related-Side-Effects/77045
https://www.clinicaloncology.com/Solid-Tumors/Article/05-25/Colorectal-Cancer-Screening-Study/77048
https://www.clinicaloncology.com/Solid-Tumors/Article/05-25/Gastric-Cancer-Genetic-Mutations/77049
https://www.clinicaloncology.com/Solid-Tumors/Article/05-25/-FDA-Approves-Welireg-for-Pheochromocytoma-and-Paraganglioma/77151
https://www.clinicaloncology.com/Solid-Tumors/Article/05-25/FDA-Grants-Accelerated-Approval-to-Emrelis-for-NSCLC-With-High-C-Met-Protein-Overexpression/77152
https://www.clinicaloncology.com/Solid-Tumors/Article/05-25/FDA-Approves-Zynyz-for-Squamous-Cell-Carcinoma-of-the-Anal-Canal/77155
https://www.clinicaloncology.com/Solid-Tumors/Article/05-25/Pancreatic-Duct-Brush-Cytology-Accuracy/77188
https://www.clinicaloncology.com/Current-Practice/Article/05-25/Healthcare-Data-Breach-Increase/77187
https://www.clinicaloncology.com/Solid-Tumors/Article/05-25/Study-Assesses-Immune-Related-AEs-in-Genitourinary-Cancer-Patients/77189
https://www.clinicaloncology.com/Current-Practice/Article/05-25/Trump-Executive-Orders-Pharmaceuticals/77249
https://www.clinicaloncology.com/Solid-Tumors/Article/06-25/Rates-of-Cervical-Precancers-Have-Fallen-Drastically-During-Vaccine-Age/77255
https://www.clinicaloncology.com/Solid-Tumors/Article/06-25/New-Treatment-Strategy-Proposed-for-Some-Patients-With-HR-Positive-HER2-Negative-Advanced-Breast-Cancer/77265
https://www.clinicaloncology.com/Solid-Tumors/Article/06-25/Structured-Exercise-Improves-Survival-in-Stage-II-III-Colon-Cancer/77270
https://www.clinicaloncology.com/Solid-Tumors/Article/06-25/-FDA-Approves-Nubeqa-for-Metastatic-Castration-Sensitive-Prostate-Cancer/77299
https://www.clinicaloncology.com/Solid-Tumors/Article/06-25/Mailed-Fecal-Immunochemical-Testing-Colorectal-Cancer-Screening/77256
https://www.clinicaloncology.com/Community-Oncology/Article/06-25/Obesity-Impact-Beta-Lactam-Antibiotics-Treatment/77335
https://www.clinicaloncology.com/Community-Oncology/Article/06-25/Meitheal-Pharmaceuticals-Launches-Generic-Paclitaxel/77339
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/06-25/Pemivibart-COVID-19-Infection-CLL/77336
https://www.clinicaloncology.com/Community-Oncology/Article/06-25/Cancer-Cachexia-Treatment-Challenges/77337
https://www.clinicaloncology.com/Community-Oncology/Article/06-25/Recurrent-CDI-Strategies/77338
https://www.clinicaloncology.com/Solid-Tumors/Article/06-25/FDA-Approves-Ibtrozi-for-ROS1-Positive-NSCLC/77399
https://www.clinicaloncology.com/Current-Practice/Article/06-25/Pharmacy-Cybersecurity-Priorities/77340
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/06-25/Novel-Therapy-Found-Effective-for-Polycythemia-Vera-in-Phase-3-Trial/77408
https://www.clinicaloncology.com/Solid-Tumors/Article/06-25/Zusduri-Approved-for-Recurrent-Low-Grade-Intermediate-Risk-Non-Muscle-Invasive-Bladder-Cancer/77438
https://www.clinicaloncology.com/Solid-Tumors/Article/06-25/FDA-Approves-Neoadjuvant-and-Adjuvant-Keytruda-for-Resectable-Locally-Advanced-Head-and-Neck-SCC/77447
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/06-25/ASH-Commits-More-Than-12-Million-to-Address-Research-Funding-Gaps/77442
https://www.clinicaloncology.com/Solid-Tumors/Article/06-25/FMT-Enhances-Immunotherapy-Effectiveness/77459
https://www.clinicaloncology.com/Solid-Tumors/Article/06-25/T-DXd-Pertuzumab-Breast-Cancer/77460
https://www.clinicaloncology.com/Solid-Tumors/Article/06-25/Imfinzi-Immunotherapy-Gastric-Cancer/77461
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/06-25/CAR-T-Therapy-Cost-Management/77463
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/06-25/FDA-Approves-Monjuvi-for-Relapsed-or-Refractory-Follicular-Lymphoma/77513
https://www.clinicaloncology.com/Community-Oncology/Article/06-25/Malnutrition-Tests-Outpatient-Oncology/77464
https://www.clinicaloncology.com/Solid-Tumors/Article/06-25/FDA-Grants-Accelerated-Approval-to-Datroway-for-Some-Patients-With-EGFR-Mutated-NSCLC/77535
https://www.clinicaloncology.com/Community-Oncology/Article/06-25/What-Exactly-Qualifies-as-a-Complex-UTI/77465
https://www.clinicaloncology.com/Community-Oncology/Article/06-25/Healthcare-AI-Safety-Concerns/77466
https://www.clinicaloncology.com/Solid-Tumors/Article/06-25/Managing-Immunotherapy-Related-GI-Complications/77472
https://www.clinicaloncology.com/Current-Practice/Article/07-25/AI-Prescribing-Medications-Legislation/77473
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/07-25/FDA-Grants-Accelerated-Approval-to-Lynozyfic-for-Relapsed-or-Refractory-Multiple-Myeloma/77612
https://www.clinicaloncology.com/Solid-Tumors/Article/07-25/FDA-Grants-Accelerated-Approval-to-Zegfrovy-for-Some-Patients-With-Metastatic-NSCLC/77616
https://www.clinicaloncology.com/Solid-Tumors/Article/07-25/ADCs-Gynecologic-Malignancies-Management-Toxicities/77474
https://www.clinicaloncology.com/COVID-19/Article/07-25/Steroid-Use-During-COVID-19-Creates-Perfect-Storm-for-Fungal-Infections/77533
https://www.clinicaloncology.com/COVID-19/Article/07-25/RFK-Jr-Vaccine-Lawsuit-IDSA/77638
https://www.clinicaloncology.com/Hematologic-Malignancies/Article/07-25/-FDA-Eliminates-REMS-for-6-CAR-T-Cell-Immunotherapies/77639
https://www.clinicaloncology.com/COVID-19/Article/07-25/VYD2311-COVID-19-Antibody-Invivyd/77646
https://www.clinicaloncology.com/Community-Oncology/Article/07-25/Survey-Identifies-Challenges-in-Delivering-Latest-Innovations-to-Cancer-Patients/77579
https://www.clinicaloncology.com/Current-Practice/Article/07-25/Book-Aims-to-Help-Individuals-Manage-Burnout/77580
https://www.clinicaloncology.com/Solid-Tumors/Article/07-25/FDA-Approves-SIR-Spheres-for-Unresectable-HCC/77682
https://www.clinicaloncology.com/Solid-Tumors/Article/07-25/Obesity-Severity-Increases-Esophageal-Cancer/77581
https://www.clinicaloncology.com/Solid-Tumors/Article/07-25/Blood-Based-Colorectal-Cancer-Screening-Test/77582
https://www.clinicaloncology.com/Current-Practice/Article/07-25/Medically-Integrated-Dispensing-Is-Best-for-Oncology-Patients/77583
https://www.clinicaloncology.com/Current-Practice/Article/07-25/Fungal-Infections-Testing-Options/77584
https://www.clinicaloncology.com/Genitourinary-Cancers/Article/07-25/New-Standard-of-Care-for-Metastatic-Castration-Sensitive-Prostate-Cancer/77640
https://www.clinicaloncology.com/COVID-19/Article/07-25/COVID-19-Impact-2025/77683
https://www.clinicaloncology.com/Solid-Tumors/Article/07-25/More-Data-on-Role-of-Statins-in-Prevention-of-HCC-and-Chronic-Liver-Disease/77684
https://www.clinicaloncology.com/Current-Practice/Article/07-25/HALT-Act-Would-Recategorize-Fentanyl-as-a-Schedule-I-Controlled-Substance-Is-That-a-Good-Thing/77685
https://www.clinicaloncology.com/Current-Practice/Article/08-25/Regional-Anesthesia-and-Cancer-Outcomes-Where-Are-We-Now/77686
https://www.clinicaloncology.com/Solid-Tumors/Article/08-25/Low-Dose-Olanzapine-Effective-for-CINV-Without-Sedation-Effects/77788
https://www.clinicaloncology.com/Solid-Tumors/Article/08-25/ctDNA-Blood-Test-Colorectal-Cancer/77793
https://www.clinicaloncology.com/Current-Practice/Article/08-25/Survey-Managing-Specialty-Drug-Costs-a-Rising-Concern-Among-Employers-Health-Plans/77794
https://www.clinicaloncology.com/Solid-Tumors/Article/08-25/Robotic-Surgery-Benefits-Rectal-Cancer/77795